Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...
The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...
According to the investigators of a newly published study on the waning of pneumococcal vaccines responses in people with inflammatory arthritis, pneumonia is a major cause of mortality in this ...
Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.
SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting both paediatric and adult populations. This partnership extension ...
Zacks.com on MSN6d
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase IIISanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...
(RTTNews) - Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation pneumococcal vaccines for both pediatric and adult ...
Conner: Tell us about the new recommendations for the pneumonia vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback